Evidence map›Paper›PMID 35681474›Full record

ReviewCells2022

The Outside-In Journey of Tissue Transglutaminase in Cancer.

Livia Elena Sima, Daniela Matei, Salvatore Condello

Open access · goldAbstract readReview
In one paragraph

Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. The role of CSTF2 in gastric cancer: implications for therapy.European journal of medical research · 2025
    Article
  9. Article
  10. Premetastatic niche mechanics and organotropism in breast cancer.npj biological physics and mechanics · 2025
    Review
  11. Review
  12. The Role of Transglutaminase 2 in Cancer: An Update.International journal of molecular sciences · 2024
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Livia Elena SimaDepartment of Molecular Cell Biology, Institute of Biochemistry of the Romanian Academy, 060031 Bucharest, Romania.ORCID 0000-0002-3404-4162
Daniela MateiDepartment of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.ORCID 0000-0003-2169-5035
Salvatore CondelloDepartment of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.ORCID 0000-0003-4979-3681
Indiana University Health · USInstitute of Biochemistry · RONorthwestern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tissue transglutaminase (TG2) is a member of the transglutaminase family that catalyzes Ca

Indexed as

NeoplasmsProtein Glutamine gamma Glutamyltransferase 2Epithelial-Mesenchymal TransitionGTP-Binding ProteinsGuanosine TriphosphateHumansTransglutaminasesGTP-Binding ProteinsGuanosine TriphosphateProtein Glutamine gamma Glutamyltransferase 2TGM2 protein, humanTransglutaminasescancercancer stem cellsextracellular matrixfibronectinimmune cellsintegrintherapytissue transglutaminasetumor microenvironment

Identifiers

PMID35681474
PMCPMC9179582
OpenAlexW4281619645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.